Apellis Pharmaceuticals (APLS) Prices 9.5M Share Offering at $37/Sh

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1.425 million additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on January 13, 2020, subject to customary closing conditions.

Citigroup, J.P. Morgan and Evercore ISI are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. and Baird are acting as lead managers for the offering.

You May Also Be Interested In

• Rivian prices $1.16B stock offering at $15.50 per share
• JPMorgan Reiterates Underweight Rating on DSM-Firmenich AG (DSFIR:NA), Places on Negative CW
• Meridian3 Industrials closes $201.25M IPO on Nasdaq